GT Biopharma, Inc.

NasdaqCM:GTBP Stock Report

Market Cap: US$16.1m

GT Biopharma Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Michael Breen

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage37.10%
CEO tenure4.3yrs
CEO ownership0.7%
Management average tenureno data
Board average tenure2.1yrs

Recent management updates

Recent updates

Analysis Article • Jan 06

We're Keeping An Eye On GT Biopharma's (NASDAQ:GTBP) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 13

GT Biopharma files for $150M mixed shelf offering

GT Biopharma (NASDAQ:GTBP) has filed for a $150M mixed shelf offering. The filing does not necessarily indicate that a sale has begun, or will occur in the future. The company intends to use the proceeds for general corporate purposes. The offering can include common stock and warrants. Seeking Alpha's Quant Rating views GT Biopharma (GTBP) as a hold.
Analysis Article • Sep 21

We Think GT Biopharma (NASDAQ:GTBP) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Aug 11

GT Biopharma GAAP EPS of -$0.10 beats by $0.07

GT Biopharma press release (NASDAQ:GTBP): Q2 GAAP EPS of -$0.10 beats by $0.07. The Company had total cash, cash equivalents and short-term investments of $23.7 million as of June 30, 2022, compared to $32.0 million as of December 31, 2021. This is expected to provide ample runway to fund operations into 2023.
Analysis Article • Jun 08

Here's Why We're Watching GT Biopharma's (NASDAQ:GTBP) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Nov 24

Companies Like GT Biopharma (NASDAQ:GTBP) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

CEO Compensation Analysis

How has Michael Breen's remuneration changed compared to GT Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$37m

Dec 31 2025US$2mUS$641k

-US$34m

Sep 30 2025n/an/a

-US$9m

Jun 30 2025n/an/a

-US$9m

Mar 31 2025n/an/a

-US$12m

Dec 31 2024US$1mUS$556k

-US$13m

Sep 30 2024n/an/a

-US$12m

Jun 30 2024n/an/a

-US$11m

Mar 31 2024n/an/a

-US$10m

Dec 31 2023US$2mUS$556k

-US$8m

Sep 30 2023n/an/a

-US$10m

Jun 30 2023n/an/a

-US$15m

Mar 31 2023n/an/a

-US$16m

Dec 31 2022US$2mUS$493k

-US$21m

Sep 30 2022n/an/a

-US$33m

Jun 30 2022n/an/a

-US$32m

Mar 31 2022n/an/a

-US$34m

Dec 31 2021US$3mUS$63k

-US$58m

Compensation vs Market: Michael's total compensation ($USD1.73M) is above average for companies of similar size in the US market ($USD642.98K).

Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.

CEO

Michael Breen (63 yo)

4.3yrs
Tenure
US$1,727,647
Compensation

Mr. Michael Martin Breen, LL B serves as Chief Executive Officer at GT Biopharma, Inc. since April 29, 2025 and serves as an Executive Chairman since November 08, 2021 and also serves as its President He s...

Board Members

NamePositionTenureCompensationOwnership
Michael Breen
President5.4yrsUS$1.73m0.68%
$ 108.9k
Charles Casamento
Independent Director3.1yrsUS$131.88k0.17%
$ 27.9k
Hilary Kramer
Independent Director1.1yrsUS$75.69k0%
$ 0
David Mun-Gavin
Independent Director1yrUS$69.55k0%
$ 0
2.1yrs
Average Tenure
70.5yo
Average Age

Experienced Board: GTBP's board of directors are not considered experienced ( 2.1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/14 19:37
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

GT Biopharma, Inc. is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Justin WalshB. Riley Securities, Inc.
Charles ButlerRoth Capital Partners
Jonathan AschoffRoth Capital Partners